The manufacturers of a high caffeine anti hair loss shampoo have assured consumers across the globe that their product is safe amid spiraling concern over the effects of heavy doses of caffeine on humans.
Dr Wolff, the manufacturer of Alpecin caffeine shampoo, has embarked on a global information campaign to counter worries over caffeine. In a statement published in seven countries, Dr Wolff points out that - just as in medicine - the effect of Alpecin on hair loss is based on the correct dosage of caffeine.
Dr Wolff said scientific studies have shown that the caffeine content in Alpecin is at levels that help develop its growth promoting effect in the hair root itself.
The information campaign comes as consumer associations increasingly demand warning labels and more education on products containing caffeine -- particularly since recent reports of the consequences of a New Zealand woman's excessive consumption of caffeine-containing cola.
In Europe, the EU is expected to publish new regulations governing products containing caffeine next year and in the US, the FDA is constantly clamping down on high caffeine content products which have adverse effects on consumers.
In addition to its global information campaign, Dr Wolff is reviewing its packaging information. Alpecin is available in South Africa and notched up record sales last year due to its efficacy.
Dr Wolff, the manufacturer of Alpecin caffeine shampoo, has embarked on a global information campaign to counter worries over caffeine. In a statement published in seven countries, Dr Wolff points out that - just as in medicine - the effect of Alpecin on hair loss is based on the correct dosage of caffeine.
Dr Wolff said scientific studies have shown that the caffeine content in Alpecin is at levels that help develop its growth promoting effect in the hair root itself.
The information campaign comes as consumer associations increasingly demand warning labels and more education on products containing caffeine -- particularly since recent reports of the consequences of a New Zealand woman's excessive consumption of caffeine-containing cola.
In Europe, the EU is expected to publish new regulations governing products containing caffeine next year and in the US, the FDA is constantly clamping down on high caffeine content products which have adverse effects on consumers.
In addition to its global information campaign, Dr Wolff is reviewing its packaging information. Alpecin is available in South Africa and notched up record sales last year due to its efficacy.
